All In Biotech

Drug Trial Radar · NCT05133336

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects With Primary Biliary Cholangitis

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

196

Actual

Start

Apr 1, 2022

Primary completion

Apr 30, 2025

Study completion May 7, 2025

Sponsor

Lead sponsor
Zydus Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Nov 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC)

Conditions

  • Primary Biliary Cholangitis

Interventions

  • Saroglitazar Magnesium 1 mgDrug

    Subjects randomized to Saroglitazar Magnesium 1 mg arm will receive Saroglitazar Magnesium 1 mg treatment for the entire treatment period up to Week 52.

  • Saroglitazar Magnesium 2 mgDrug

    Subjects randomized to Saroglitazar Magnesium 2 mg arm are switched to Saroglitazar Magnesium 1 mg treatment up to Week 52

  • PlaceboDrug

    Subjects randomized to placebo arm will receive placebo treatment for the entire treatment period up to Week 52.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with biochemical response based on the composite endpoints of ALP and total bilirubinTime frame: From baseline to week 52

Locations

57 sites in 4 countries. Site status is shown where the registry gives one.

  • Zydus US007

    Birmingham, Alabama

  • Zydus US021

    Tucson, Arizona

  • Zydus US013

    Los Angeles, California

  • Zydus US011

    Pasadena, California

  • Zydus US043

    Sacramento, California

  • Zydus US022

    Aurora, Colorado

  • Zydus US037

    New Haven, Connecticut

  • Zydus US027

    Jacksonville, Florida

  • Zydus US006

    Lakewood Rch, Florida

  • Zydus US005

    Miami, Florida

  • Zydus US028

    Sarasota, Florida

  • Zydus US019

    Tampa, Florida

  • Zydus US020

    Marietta, Georgia

  • Zydus US001

    Indianapolis, Indiana

  • Zydus US034

    Iowa City, Iowa

  • Zydus US036

    Marrero, Louisiana

  • Zydus US023

    Rochester, Minnesota

  • Zydus US030

    St Louis, Missouri

  • Zydus US024

    Omaha, Nebraska

  • Zydus US038

    Manhasset, New York

  • Zydus US035

    Rochester, New York

  • Zydus US002

    Charlotte, North Carolina

  • Zydus US014

    Cincinnati, Ohio

  • Zydus US015

    Philadelphia, Pennsylvania

  • Zydus US004

    Houston, Texas

  • Zydus US042

    Houston, Texas

  • Zydus US031

    Murray, Utah

  • Zydus US016

    Charlottesville, Virginia

  • Zydus US041

    Newport News, Virginia

  • Zydus US039

    Richmond, Virginia

  • Zydus US033

    Seattle, Washington

  • Zydus AR004

    Buenos Aires, Argentina

  • Zydus AR009

    Buenos Aires, Argentina

  • Zydus AR001

    Buenos Aires, Argentina

  • Zydus AR013

    Buenos Aires, Argentina

  • Zydus AR007

    Buenos Aires, Argentina

  • Zydus AR006

    Buenos Aires, Argentina

  • Zydus AR005

    Buenos Aires, Argentina

  • Zydus AR012

    Buenos Aires, Argentina

  • Zydus AR003

    Buenos Aires, Argentina

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.